Southern Medical University

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Retrieved on: 
Wednesday, March 27, 2024
Multiple, Professor, ETV, SAN, Patient, Hepatology, Southern Medical University, SHBG, Doctor of Science, University, Doctor of Philosophy, MBBS, MASH, MBA, Science, Therapy, Hepatitis, Part, Division, University of Hong Kong, Infection, CHB, Pharmaceutical industry

The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.

Key Points: 
  • The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.
  • “We are pleased to present these additional Phase 1 data for ALG-055009 and ALG-000184 at APASL 2024.
  • We continue to believe our molecule has the potential to be best-in-class,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • “In addition, the three ALG-000184 oral presentations demonstrate a consistent effect in the reduction of key viral markers.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Cohort, Medicine, Abstract, NSCLC, GBM, APLM, Hospital, IDH, ESMO, SPARTA, European Society for Medical Oncology, Southern Medical University, Yang, Patient, Poster, Pharmaceutical industry, Nursing

FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.

Key Points: 
  • FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.
  • The poster will include data from patients with METex14 mutation (Cohort 1) from the Phase 2, open-label, multicenter and multi-cohort study.
  • "Vebreltinib continues to yield compelling data, reinforcing its potential as a vital treatment option for patients with challenging-to-treat cancers driven by c-MET alterations,” said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics.
  • Presentation materials will be available on the Apollomics website following the presentations at ESMO: https://ir.apollomicsinc.com/news-events/presentations .

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Retrieved on: 
Thursday, October 20, 2022
CDE, Merck, Therapy, Mayo Clinic, Institute, Treatment, American Association, Association, Congress, The Pauly D Project, Priority review, BTD, California Department of Alcohol and Drug Programs, Cancer, NMPA, Infection, CHB, Motherboard, Degenerative disease, Hepatology, Odds, FDA, Biotechnology, RPD, AstraZeneca, FTD, DC, National Medical Products Administration, Hepatitis, Multimedia, TKI, Jingxi Nanfang Hospital station, Apoptosis, AASLD, IAP, Unity Biotechnology, Southern Medical University, Patient, Stock exchange, Center for Drug Evaluation and Research, ODD, CML, MD Anderson Cancer Center, Institute of Liver and Biliary Sciences, Center, Dana–Farber Cancer Institute, Pharmaceutical industry, Vaccine, Fine chemical, Pfizer, EU

The AASLD Annual Meeting is one of the most anticipated scientific gatherings in the field of hepatology.

Key Points: 
  • The AASLD Annual Meeting is one of the most anticipated scientific gatherings in the field of hepatology.
  • This year's congress will take place both online and in-person in Washington, DC, the United States, during November 4th to 8th, 2022.
  • Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
  • Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

2022 Report on the Survey of Global Generation Z Released

Retrieved on: 
Friday, May 27, 2022
Department, Generation, Generation Z, Gen Z GOP, Climate change, Chinese Academy of Social Sciences, Human, Multimedia, Political science, School, Trust, Poverty, Gen, Research, United Kingdom, Institute, China Youth University of Political Studies, Tsinghua University, Ministry of Women and Child Development, Creativity, Communication, Social science, Kyiv International Institute of Sociology, Pressure, Journalism, Public policy, Perception, Peking University, Anxiety, Technology, Youth Power, Attention, Economic development, Education Development Center, UNDP, Fudan University, Social Security, United Nations, Achievement, International Journal of Innovation and Technology Management, Renewable energy, Toy, Tobacco, Southern Medical University, Sociology, China Daily

The report, entitled the "2022 Global Generation Z Insights Report" was unveiled during an opening ceremony for the Generation Z Research Center in Beijing on May 27, 2022.

Key Points: 
  • The report, entitled the "2022 Global Generation Z Insights Report" was unveiled during an opening ceremony for the Generation Z Research Center in Beijing on May 27, 2022.
  • The 2022 Global Generation Z Insights Report is the very first report released by the new center,striving to present a well-rounded and realistic picture of a global Generation Z, including of their self-perception, life attitudes, social contact preferences, consumption habits, opinions on technology, and thoughts on social and international relations.
  • In interviews conducted by the Generation Z Research Center, many overseas Generation Z interviewees said their perceptions changed significantly once they had been to China.
  • Xue believed that with the rapid development of Internet technology and the growing power of youth, 2022 Global Generation Z Insights Report is of great importance in strengthening the study of Generation Z and cultivating the broad vision and cultural confidence of Chinese and overseas Generation Z.

Traditional Chinese Medicine, Shengmai Yin, May Improve the Effects of Radiation Therapy, Says New Study in Journal of Pharmaceutical Analysis

Retrieved on: 
Tuesday, March 1, 2022
Nasopharyngeal carcinoma, Cell, SP1, Herbal medicine, Radiation, Gene, University, Research, Mutation, Cancer, Nose, DNA methylation, DNA, Methylation, Phytochemical, CpG, TNC, Patient, Quality of life, Southern Medical University, Genetic code, Mortality, Jingxi Nanfang Hospital station, SMY, Vaccine, Pharmaceutical industry, NPC

Radioresistance can be mitigated by the use of 'radiosensitizers,' chemical compounds that make cells more vulnerable to radiation.

Key Points: 
  • Radioresistance can be mitigated by the use of 'radiosensitizers,' chemical compounds that make cells more vulnerable to radiation.
  • The findings of the study shed light on three very important aspects of SMY as a therapeutic supplement during radiotherapy.
  • SMY has the potential to be a safe, effective and economically viable radiosensitizer and therapeutic supplement to radiation therapy.
  • Developing pharmaceuticals based on this traditional Chinese medicine could help improve the quality of life and reduce the mortality of patients with NPC.